source
- BridgeBio's heart drug Attruby exceeds sales expectations, shifting investor outlookBridgeBio prepared to sell its heart drug Attruby on its own, prompting skepticism from investors and analysts who doubted the company could compete with larger rivals. The drug far outperformed f…
- Novartis CEO warns of impact from Germany's €60 billion healthcare spending cutsNovartis chief executive Vas Narasimhan said the company is very disappointed by Germany's proposal to reduce healthcare spending by more than €60 billion. He expressed concern that the cuts could…